SoundRidge Private Wealth Debuts in NYC
2025 Forbes Best-in-State Wealth Management Team Joins Wells Fargo Advisors Financial Network (FiNet) NEW YORK–(BUSINESS WIRE)–Veteran advisors Noah... Read more.
Vicarious Surgical Receives Continued Listing Standard Notice from the NYSE
WALTHAM, Mass.–(BUSINESS WIRE)–Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics... Read more.
Generis Group Recognized Among The Americas’ Fastest-Growing Companies 2025 by the Financial Times and Statista
The company ranks with a three-year absolute revenue growth rate of 123% TORONTO–(BUSINESS WIRE)–Generis Group, an award-winning global B2B event organizer,... Read more.
Alliant Energy Corporation Announces First Quarter Earnings Release and Conference Call
MADISON, Wis.–(BUSINESS WIRE)–Alliant Energy Corporation (NASDAQ: LNT) has scheduled its first quarter earnings release for Thursday, May 8th, after... Read more.
Helix Announces First Quarter Earnings Release Date and Conference Call Information
HOUSTON–(BUSINESS WIRE)–Helix Energy Solutions Group, Inc. (NYSE: HLX) will issue a press release reporting its first quarter 2025 results on Wednesday,... Read more.
FiscalNote Receives Continued Listing Notice From NYSE
Company Afforded Standard Six-Month Cure Period To Regain Listing Compliance Management Remains Focused on Strategy Execution, Paying Down Debt, Leveraging New PolicyNote... Read more.
Angel Oak Financial Strategies Income Term Trust Announces Rights Offering and Monthly Distribution
ATLANTA–(BUSINESS WIRE)–$FINS–Angel Oak Financial Strategies Income Term Trust (NYSE: FINS) (the “Fund”) today announced that its Board of... Read more.
Docebo to Host First Quarter Fiscal 2025 Conference Call
TORONTO–(BUSINESS WIRE)–Docebo Inc. (Nasdaq:DCBO; TSX:DCBO) (“Docebo” or the “Company“), a leading learning platform provider... Read more.
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
Based on the Phase 3 CheckMate-9DW trial, Opdivo plus Yervoy demonstrated a statistically significant overall survival benefit compared to investigator’s choice... Read more.
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
Based on the Phase 3 CheckMate-9DW trial, Opdivo plus Yervoy demonstrated a statistically significant overall survival benefit compared to investigator’s choice... Read more.